Navigation Links
Biologics valuable treatment option for patients with inflammatory bowel disease

The use of biologic agents for the treatment of inflammatory bowel disease (IBD) may benefit patients, but doctors need to consider the potential associated side effects in determining treatment course, according to a consensus paper published in this month’s issue of Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute. IBD includes Crohn’s disease and ulcerative colitis, both frequently disabling diseases that affect approximately one million people both in the U.S. and Europe.

The conference examined the literature on monoclonal antibodies or antibody fragments currently approved by the FDA or likely to be approved in the near future. The participants of the Consensus Development Conference, medical experts in IBD convened by the AGA Institute, sought to answer a series of questions about the treatment of IBD with these biologics based on expert presentations of current scientific knowledge about IBD and subsequent discussion. Co-chairs of the conference were Stephen B. Hanauer, MD, professor of medicine and clinical pharmacology at the University of Chicago, and Paul Rutgeerts, MD, AGAF, professor of medicine, University Hospital Gasthuisberg, Belgium.

“The management of inflammatory bowel disease has been significantly affected by the development of biologic therapies,” according to Dr. Hanauer. “Biologic therapies provide new options and hope for many patients, however they may be accompanied by serious side effects, both when used alone or in combination with other treatments. Gastroenterologists need to review and consider the side effects and significant costs when determining the best treatment course for their patients.”

The treatment goal for IBD patients has been to alleviate symptoms associated with these diseases and many gastroenterologists rely on a “step up” or sequential treatment approach in treating their patients depending on the severity of their disease. Resea
'"/>




Page: 1 2 3

Related medicine news :

1. Generic Biologics – U.S Panel Hearing Draws Mixed Response
2. Shapely sperm-a valuable indicator of fertility
3. Autopsy reports could be valuable and informative
4. Measuring disseminated cancer cells in bone marrow - valuable tool for detecting early breast cancer metastasis
5. Reindeer Provide Valuable Insights Into Sleep Disorders
6. Poverty Claims Valuable Lives Of Children In Orissa
7. Advances in Treatment of Cataracts
8. Recommendations for Treatment of Blood Pressue
9. Thyroid hormone treatment hastens recovery after cardiac surgery
10. Feeding channel created by malaria parasite - a new target for malaria treatments
11. Now umbilical cord helps in stroke treatment.
Post Your Comments:
(Date:7/23/2008)...to Meet the Financing Needs of European and ...-, NEW YORK, July 24 /PRNewswire/ -- Paul Capital... has been promoted to Partner. Based in Paul,Capit... sourcing,evaluating and negotiating European and... Paul Capital Healthcare funds., "Since he joined...
(Date:7/23/2008)... /PRNewswire/ -- MediVoice(R), LLC, the,world,s fi...and,e-Prescribing, has formed a strategic partners...ractive, web-based, patient-centered health record...integrate and market its,mobile voice-activation s...) system., "MediVoice is pleased to develop a str...
(Date:7/23/2008)...wire/ -- Philip J. Dwyer, president and CEO,of the... before the U.S.,Senate Health, Education, Labor, ...nd Families today to call for increased funds for ...ed at YMCAs across the nation, that will,help redu...on behalf of the more than 2,600 YMCAs, that -- fo...
(Date:7/23/2008)...gration and Naturalization ready at Passport ...y 23 /PRNewswire/ -- New vaccine requirements will...sa for entry into the U.S. and,anyone seeking adju...ts,must show proof of vaccinations against vaccine...Advisory Committee on Immunization Practices.,Pass...
Breaking Medicine News(10 mins):Health News:Paul Capital Partners Promotes Ken Macleod To Partner 2Health News:Paul Capital Partners Promotes Ken Macleod To Partner 3Health News:MediVoice(R) Partners With VisionTree(R) to Integrate Its Voice-Activated e-Prescribing Solution Into VisionTree's VTOC(TM) Web-Based Patient Management System 2Health News:MediVoice(R) Partners With VisionTree(R) to Integrate Its Voice-Activated e-Prescribing Solution Into VisionTree's VTOC(TM) Web-Based Patient Management System 3Health News:YMCA Calls on Senate to Fund Community-Based Solutions to Address Childhood Obesity Crisis 2Health News:YMCA Calls on Senate to Fund Community-Based Solutions to Address Childhood Obesity Crisis 3Health News:USCIS Tightens Vaccination Requirements 2
... Health says many smokers are yet to understand th...warning pictures are an effective// way to get the...r of Health, Damien O'Connor, today launched a pro...ackets. The Ministry wants feedback on whether he...
...ol of Business (ISB) Tuesday signed a memorandum o...derabad-based real estate company, to establish// ...n studies'. This is said to be the first such st...chool in India. It is also the first research cha...
... found a gene that increased Type 2 diabetes in ov...d new treatment for the condition in humans. // T...ition, with an estimated 16 million Americans affl...en, the development of the disease is caused by ob...
...high on fiber is perhaps the first thing that doct...offsetting hemorrhoids. // Hemorrhoids, a conditio...n and around the anus that can give rise to bleedi...erican Society of Colon and Rectal Surgeons, hemor...
Other Medicine News:Health News:New Zealand To Issue Graphic Warnings In Cigarette Packs 2
(Date:7/22/2008)...ment Plan Completed Successfully, DUBLIN, Ireland...tion,plc (NASDAQ: AMRN ) today announced that the...ood and Drug Administration (FDA) to discuss the,C... of,hypertriglyceridemia. Following these discussi...101 in hypertriglyceridemia., Dr. Declan Doogan, ...
(Date:7/22/2008)... 22 /- Hyperion,Therapeutics, Inc. to...ment,in its Phase 1/2 clinical trial to evaluate t...ects of HPN-100 (formally called GT4P) versus,BUPH...rea cycle disorders,(UCD). The company plans to an...his year., (Logo: http://www.newscom.com/cgi-bin...
(Date:7/22/2008)...enetic Risk Based on Clinical Data, Preventive ...als, WALTHAM, Mass., July 22 /PRNewswire-FirstCal...day announced the launch of an enhanced test repor... Heart Health Genetic Test.,The test is currently ...lth,Genetic Test by Quixtar/Amway. The new report ...
(Date:7/21/2008)...he SEAS (Simvastatin and Ezetimibe in,Aortic Steno...ve,cholesterol lowering with the combination of si...) in patients with aortic stenosis., Aortic steno... valve in,the heart) is a relatively common diseas...untreated, it can progress to death from heart fai...
Breaking Medicine Technology:Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 2Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 3Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 2Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 3Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format 2Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format 3Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 2Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 3Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 4Six Positive Predictions for 2008 from SuperLife World Service 8518 1Six Positive Predictions for 2008 from SuperLife World Service 8518 2K2 Sports Announces New Endurance Suncare Product Rollout for 2008 8515 1K2 Sports Announces New Endurance Suncare Product Rollout for 2008 8515 2K2 Sports Announces New Endurance Suncare Product Rollout for 2008 8515 3AMDLs First Full Service JPGreen Health and Personal Care Center Set to Open in Hangzhou China 2287 1AMDLs First Full Service JPGreen Health and Personal Care Center Set to Open in Hangzhou China 2287 2Widespread support for nonembryonic stem cell research VCU Life Sciences Survey shows 1666 1Widespread support for nonembryonic stem cell research VCU Life Sciences Survey shows 1666 2
...n 5, 2007 - Elixir,Pharmaceuticals, Inc., announce...tagonism as a potential method for regulating,meta...glucose. The,data were presented in poster session...ual Meeting, being held in Toronto,Canada. Elixir...nd,prevent metabolic disease, as well as prevent a...
...k,comparable to two widely used diabetes medicines...more than 33,000 type 2 diabetes patients in a rea...ows that the incidence of,hospitaliations for hear...evascularization for patients on Avandia is the,...esults were,released in a paper titled “Coro...
Other Medicine Technology:Elixir Pharmaceuticals Presents Additional Preclinical Data,Demonstrating the Potential of Ghrelin Antagonism to Regulate,Metabolism, Body Weight and Glycemic Control 2Elixir Pharmaceuticals Presents Additional Preclinical Data,Demonstrating the Potential of Ghrelin Antagonism to Regulate,Metabolism, Body Weight and Glycemic Control 3Elixir Pharmaceuticals Presents Additional Preclinical Data,Demonstrating the Potential of Ghrelin Antagonism to Regulate,Metabolism, Body Weight and Glycemic Control 4Newly Published Data from Large Study Support Cardiovascular Safety,of Avandia (Rosiglitazone Maleate) 2Newly Published Data from Large Study Support Cardiovascular Safety,of Avandia (Rosiglitazone Maleate) 3Newly Published Data from Large Study Support Cardiovascular Safety,of Avandia (Rosiglitazone Maleate) 4
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations.
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations.
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations.
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations.
Medicine Products: